A Phase 1b Study of PU-H71 With Nab-paclitaxel (Abraxane) in Patients With HER2-Negative Metastatic Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2019
Price : $35 *
At a glance
- Drugs PU H71 (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 17 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Aug 2018 Planned End Date changed from 1 May 2018 to 1 May 2020.
- 07 Aug 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2020.